Healthcare / Medical DevicesHKSE
$4.72
-0.13 (-2.68%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-325.3M · quality 69.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
21/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.2B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-11.0%
↓Gross Margin
68.2%
↑Debt/Equity
0.24
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+41.6%
FCF CAGR
—
FCF margin
-45.6%
FCF / Net income
1.60x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $712.9M · net income $-203.3M · FCF $-325.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $712.9M | $712.9M | $615.5M | $441.1M | $250.8M |
| Net Income | $-203.3M | $-203.3M | $-226.6M | $-392.5M | $-407.8M |
| EBITDA | $-123.0M | $-123.0M | $-157.8M | $-348.5M | $-359.9M |
| EPS | — | — | -0.34 | -0.58 | -0.61 |
| Gross Margin | 68.2% | 68.2% | 70.5% | 73.8% | 70.2% |
| Operating Margin | -27.4% | -27.4% | -37.4% | -94.3% | -220.0% |
| Net Margin | -28.5% | -28.5% | -36.8% | -89.0% | -162.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.24 | 0.24 | 0.12 | 0.10 | 0.05 |
| Current Ratio | 1.21 | 1.21 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-325.3M | $-325.3M | $-285.3M | $-947.1M | $-578.5M |
| Returns | |||||
| ROE | -11.0% | -11.0% | -11.2% | -17.3% | -15.5% |
| Valuation | |||||
| P/B | 1.71 | 1.71 | 1.25 | 1.94 | 2.48 |
| Growth & Yield | |||||
| Revenue Growth | 15.8% | 15.8% | 39.5% | 75.9% | — |
| EPS Growth | — | — | 41.4% | 4.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-14.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.34 → n/d
Residual
-14.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.